Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (2959)	11/27/2007 2:34:45 AM
From: Icebrg	Read Replies (1) \| Respond to of 3044

Millennium Pharmaceuticals "outperform," target price raised Monday, November 26, 2007 4:18:34 AM ET Robert W. Baird NEW YORK, November 26 (newratings.com) - Analysts at Robert W Baird reiterate their "outperform" rating on Millennium Pharmaceuticals Inc (MLNM.NAS), while raising their estimates for the company. The target price has been raised from $15 to $18. In a research note published this morning, the analysts mention that there is substantial front-line opportunity in the multiple myeloma indication for the company’s Velcade drug. Millennium Pharmaceuticals is expected to receive higher-than-previously-anticipated royalty fees from Europe for Velcade, the analysts say. The estimates have been revised to also reflect a more favourable tax rate, Robert W Baird adds. The EPS estimates for 2007 and 2008 have been raised from $0.13 to $0.15 and from $0.20 to $0.39, respectively.